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The objective of this investigation was to define the splanchnic hemodynamic effects of par- 
enterally administered glucagon in a canine model. Measurements in six dogs at baseline and at 
10, 20, and 30 min during constant intravenous infusion of glucagon at 1 pg/kglmin included: 
Cardiac output (CO), mean arterial pressure, total peripheral vascular resistance (TPR), superior 
mesenteric artery flow (SMAQ), portal venous pressure (PVP), superior mesenteric artery vascular 
resistance (SMAR), percentage SMA flow through arteriovenous anastomoses (AVA%) determined 
by 99mTc microsphere technique, as well as volume flow through AVA (AVAQ), and volume flow 
through the SMA nutrient capillary circulation (NCQ). SMAQ rose significantly and dispropor- 
tionately compared to the rise in CO. SMAQ more than doubled from a mean of 448 f 124 cc at 
baseline to a mean of 921 f 321 cc at 10 min, and remained elevated throughout drug infusion. 
SMAR and TPR both decreased significantly. Although percentage shunt was low at baseline, 
1.79 ? 0.94% and did not change, both AVAQ and NCQ increased significantly during drug 
infusion. The increase in AVAQ was transient, but NCQ remained elevated throughout infusion. 
PVP increased significantly, and the change in PVP correlated significantly with the change in 
AVAQ at 30 min, a time when AVAQ was not elevated significantly above baseline levels. Nutrient 
capillary flow comprised 298% of total SMAQ during the experiment and, along with total SMAQ, 
doubled and remained elevated throughout drug infusion. Although glucagon may increase PVP 
by slightly increasing the absolute volume of mesenteric shunt flow, its primary action is that of a 
potent mesenteric arterial dilator, increasing NCQ strikingly more than AVAQ. 
Glucagon is a polypeptide hormone that 
has a variety of actions other than its known 
hyperglycemic effect. When administered in 
pharmacologic doses, glucagon increases 
superior mesenteric artery (SMA) blood 
flow and lowers mesenteric vascular re- 
sistance [7, 15, 19, 21, 26, 29, 301. These 
splanchnic hemodynamic effects have gen- 
erally been attributed to arterial dilatation. 
Recently, the supposition that glucagon 
causes mesenteric arteriovenous shunting 
has been reintroduced into the surgical 
literature [20, 241. Previous investigators 
have shown that portal venous pressure 
and portal venous oxygen concentration 
rise during glucagon infusion, and have 
suggested that this was a reflection of 
mesenteric shunting [12, 131. To our knowl- 
edge, previous studies have not directly 
examined whether glucagon causes arterio- 
venous shunting in the superior mesenteric 
artery circulation. 
In the current investigation, the effect 
of glucagon on superior mesenteric artery 
arteriovenous anastomotic shunting was 
measured directly using the radioactive 
microsphere technique in a canine model. 
Quantification of the percentage of blood 
flow passing through superior mesenteric 
artery shunts allowed determination of the 
volume of nonshunt flow which was of a 
nutritive nature as it passed through the 
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capillary circulation. The objective of this 
experiment was to precisely define the 
mechanisms by which pharmacologic doses 
of glucagon alter superior mesenteric 
artery blood flow. 
MATERIALS AND METHODS 
Six adult mongrel dogs weighing 24 to 
37 kg were anesthetized with 30 mg/kg 
sodium pentobarbital with supplemental 
pentobarbital anesthesia (5 mg/kg) ad- 
ministered as needed. Experimental ma- 
nipulations were not performed within 40 
min of anesthetic administration. Dogs 
were intubated and mechanically ventilated 
to maintain arterial blood gases within 
physiologic range. Hypoxic dogs or those 
with abnormal acid-base status were not 
studied. An esophageal temperature probe 
was inserted for measurement of core 
temperature. Normothemia was carefully 
maintained during the experiment. Lactated 
Ringer’s solution (30 cc/kg body wt) was 
infused as a bolus during the early opera- 
tive manipulations, and 20 cc/kg/hr Ringer’s 
solution was administered over the 30 min 
when glucagon was administered and hemo- 
dynamic measurements were performed. 
A 14-gauge polyethylene carotid arterial 
catheter, a centrally threaded 21-gauge 
Teflon jugular venous catheter, and a 7- 
french thermodilution Swan-Ganz catheter 
with its tip in the pulmonary artery were 
inserted by way of the cervical vessels. 
The superior mesenteric artery was care- 
fully exposed at its origin, and a non- 
occluding, precalibrated 12- or 13-mm-di- 
ameter electromagnetic flow probe was 
placed about the proximal artery. A 21- 
gauge polyethylene catheter was inserted 
into one of the superior mesenteric artery 
arcade branches. This catheter was threaded 
into the superior mesenteric artery 2 to 3 
cm from its aortic origin, such that its tip 
was proximal to all SMA arterial branches. 
An l&gauge polyethylene catheter was 
threaded into the portal vein proximal to its 
bifurcation by way of a pancreaticoduo- 
denal branch. 
The right lobe of the liver was brought 
outside the chest through diaphragmatic 
and thoracotomy incisions. This was facili- 
tated by a generous right lateral thoracot- 
omy incision through the 9th or 10th inter- 
costal space with resection of an adjacent 
rib. Similarly, the right hemidiaphragm 
was generously incised and a portion ex- 
cised. There was no obstruction to hepatic 
arterial and portal venous inflow or hepatic 
venous outflow from the externalized liver 
segment. This maneuver did not alter portal 
venous pressure in any animal. The dis- 
located liver lobe was wrapped loosely 
with a moist laparotomy pack. A nuclear 
scanner calibrated for the detection of tech- 
netium-99m was fixed in place immedi- 
ately over the liver segment. The midline 
incision was reapproximated to secure the 
remaining abdominal contents within the 
peritoneal cavity. The abdomen and chest 
were shielded from the scanner using a 
lead apron. 
Central venous pressure, systemic ar- 
terial pressure, and portal venous pressure 
were continuously monitored using pressure 
transducers attached to a multichannel 
recorder. Cardiac output was measured by 
the thermodilution technique. Total su- 
perior mesenteric artery flow was measured 
using a carefully calibrated electromagnetic 
square wave flow probe, and was con- 
tinuously recorded on the multichannel 
recorder. 
Radioactive technetium-99m-labeled al- 
bumin microspheres with a mean diameter 
of 20 Frn were freshly prepared. These 
spheres varied in size from 10 to 35 pm such 
that only 5% of the spheres were outside 
this range. Microspheres were discarded if 
significant amounts of unlabeled radio- 
activity or gross abnormalities in size were 
detected. Less than 1% of the prepara- 
tions’ radioactivity was not bound by micro- 
spheres, as determined by instant thin- 
layer chromatography. 
Shunt flow through arteriovenous anas- 
tomotic channels (AVA) was determined 
by techniques paralleling those employed 
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for the determination of shunt in the canine 
hindlimb [3]. A known quantity of tech- 
netium-99m-labeled microspheres was in- 
jected into the superior mesenteric artery. 
The change in counts per minute over the 
externalized liver segment after injection 
was monitored using a nuclear scanner 
calibrated for measurement of ggmTc, hav- 
ing a 12.7:cm detector with a straight 
bore collimator. It was assumed that 
spheres passing through AVA in the 
mesenteric circulation would pass from the 
arterial to the portal venous circulation 
and be trapped in the liver. Delaney and 
others have shown the liver to be an ade- 
quate trap for microspheres in experiments 
measuring gastrointestinal arteriovenous 
anastomotic shunting or blood flow dis- 
tribution [5, 9, lo]. 
Spheres not passing through arterio- 
venous anastomoses would theoretically 
be trapped in the mesenteric capillary 
circulation as the mean diameter of canine 
mesenteric capillaries has been shown to 
be approximately 7.38 pm [l]. A reference 
“100% shunt” was established by meas- 
uring the change in radioactivity over the 
liver segment after injecting a known dose 
of radioactive microspheres into the portal 
vein. Data thus generated allowed for cal- 
culation of the change in counts per minute 
per microcurie injected or “shunted.” The 
actual doses injected were determined by 
using a radioisotope dose calibrator ad- 
justed to detect technetium-99m. 
Radioactivity of syringes containing the 
microspheres was measured in micro- 
curies both before and after injection. 
The actual doses injected were determined 
considering the rapid radioactive decay 
of technetium-99m. Microspheres were in- 
jected into the superior mesenteric artery 
against flow in a rapid fashion to insure 
adequate mixing [5]. Superior mesenteric 
artery total flow was not disturbed. The 
volume of microsphere injectate was 10.1 
cc and contained from 25,000 to 37,500 
microspheres. Syringes containing the micro- 
spheres were flushed slowly three times 
with 1 cc of blood aspirated through the 
polyethylene tubing. The radioactivity of 
the polyethylene tubing in the superior 
mesenteric artery and portal vein, as well 
as the stopcocks attached to this tubing, was 
minimal and was therefore not considered 
in any calculations. 
Cardiac output (CO), mean arterial pres- 
sure (MAP), central venous pressure (CVP), 
total peripheral vascular resistance (TPR 
= (MAP - CVP)/CO x 79.9 in dyn-set/ 
cm5), and superior mesenteric arterial re- 
sistance (SMAR = (MAP - PVPYSMAQ 
(liters/min) x 79.9 in dyn-sec/cm5) were 
derived in a standard fashion. The per- 
centage of superior mesenteric blood flow 
passing through arteriovenous anastomoses 
was calculated as: 
Acpm over liver after arterial injection 
% Shunt = 
actual dose of arterial injection 
x 100. 
Acpm over liver after portal venous injection 
actual dose of portal venous injection 
The volume flow through these shunts was 
calculated as: Shunt flow = total SMAQ Hemodynamic measurements were made 
x % shunt. The volume of nonshunted after achieving a stable baseline, and at 
nutrient blood flow delivered to the mesen- 10, 20, and 30 min during infusion of 1 
teric capillary circulation was calculated pg/kg/min glucagon by way of a peripheral 
using the formula: vein. Baseline determinations of shunt 
SMA nutrient flow (SMA-NCQ) levels were performed twice in each dog. Values obtained were reproducible and did 
= total SMAQ - shunt flow. not vary significantly from one another. 
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TABLE 1 
MAJOR HEMODYNAMIC EFFECTS OF GLUCAGON INFUSION 
Glucagon infusion period 
Baseline 10 mitt 20 min 30 min 
Cardiac output (Vmin) 
Mean arterial pressure 
(mm Hg) 
Total peripheral resistance 
(dyn-sec)/cmj 
4.16 k 0.74 4.71 t 1.2 (ns) 4.95 -c 1.02* 4.92 + 0.93 (ns) 
112 k 13 104 + 17* 94 rt. 16** 94 k 10* 
2274 5 359 1921 k 392** 1615 -r- 246*** 1612 + 212*** 
Note. Data assessed for statistical significance in comparison to baseline values using two-tailed paired 
t test. Measurements expressed as 2 k 1 SD. 
* P < 0.05. 
** P < 0.01. 
*** P < 0.001. 
ns, not significant. 
Lungs of several dogs were scanned, and 
minimal radioactivity was documented, 
confirming suitable hepatic trapping of 
microspheres. Pearson product-moment 
correlation coefficients were calculated 
for the various parameters making a data 
matrix with the MIDAS statistical com- 
puter program. When appropriate, linear 
regression analyses, two-tailed paired t 
tests, and Wilcoxon signed-rank tests were 
performed in a standard fashion. 
RESULTS 
Glucagon elicited major hemodynamic 
alterations (Table 1). Cardiac output was 
increased throughout the infusion. The 
cardiac output increased from a baseline 
of 4.16 t 0.74 to 4.95 4 1.02 liters/min at 
20 min infusion. This change was signifi- 
cant (P < 0.05), and the increase in cardiac 
output approached significance at 30 min 
(0.05 < P < 0.1). The infusion resulted in 
a significant and progressive decline in mean 
arterial pressure and total peripheral vas- 
cular resistance compared to baseline. 
Linear regression analysis documented that 
TPR decreased significantly with time 
through the infusion, as did MAP. 
The effect on superior mesenteric artery 
blood flow was marked (Table 2). By 10 
min, superior mesenteric artery flow vir- 
tually doubled from 448 ? 124 to 921 
-c 321 cc/min. Superior mesenteric artery 
flow remained significantly elevated for the 
duration of glucagon infusion. Mesenteric 
vascular resistance at 10 min had fallen to 
approximately half baseline levels and re- 
mained significantly lower than controls for 
the duration of the experiment. An inverse 
linear correlation between superior mesen- 
teric artery flow and resistance was docu- 
mented throughout the study (P < 0.05). 
Superior mesenteric artery blood flow did 
not appear statistically related to cardiac 
output. Importantly, superior mesenteric 
artery flow comprised a progressively 
larger portion of cardiac output during 
glucagon administration. At baseline, 10.8% 
of the cardiac output was distributed to 
the superior mesenteric circulation. At 10 
and 20 min this rose to 20.2 and 16.9%, 
respectively (P < 0.05). The dispropor- 
tionate rise in mesenteric blood flow, and 
lack of its correlation with cardiac output 
implies that increased mesenteric blood flow 
does not result solely from increased 
cardiac output. 
The percentage of blood flow shunted 
through AVA in the superior mesenteric 
arterial circulation in baseline measure- 
ments was low, 1.79 +- 0.94% (Table 2). 
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TABLE 2 
MESENTERIC MICROCIRCULATORY EFFECTS OF GLUCAGON INFUSION 
Glucagon infusion period 
Baseline 10 min 20 min 30 min 
Superior mesenteric artery flow 
(mYmin) 448 2 124 921 k 321** 828 k 260** 755 k 225** 
Portal venous (mm Hg) pressure 1.0 * 1.0 2.8 + 1.2** 3.5 k 1.7** 3.5 2 1.8* 
Superior mesenteric artery 
resistance (dyn-sec)/cm5 20,738 k 3,610 9361 k 1860*** 9194 + 1660*** 10,053 +- 2,620*** 
Percentage superior mesenteric 
artery blood flow shunted 
through AVA 1.79 * 0.94 1.61 * 0.82 (ns) 1.53 * 0.83 (ns) 1.39 2 0.75 (ns) 
Superior mesenteric artery 
AVA flow (mYmin) 7.35 k 3.6 13.1 + 6.1* 11.5 f 6.3* 9.8 * 5.9 (ns) 
Superior mesenteric artery 
nutrient capillary flow 
(mkmin) 441 ? 125 908 r 322* 818 t 262* 745 k 227* 
Note. Data assessed for statistical significance in comparison to baseline values using Wilcoxon signed-rank 
tests and two-tailed paired t test. Measurements expressed as x f 1 SD. 
* P < 0.05. 
** P < 0.01. 
*** P < 0.001. 
ns, not significant. 
This value was similar to those previously 
reported using different techniques [5, 6, 
9, 111. The percentage of SMAQ passing 
through AVA following glucagon infusion 
did not change significantly from baseline, 
although it tended to decrease. The absolute 
volume of shunt flow passing through AVAs 
significantly increased from baseline at 10 
and 20 min of glucagon infusion. The volume 
of this shunt flow was very small in com- 
parison to the increase in mesenteric 
nutrient flow. The superior mesenteric 
arterial nonshunt nutrient flow rose mark- 
edly and significantly during drug infusion, 
and comprised greater than 98% of total 
mesenteric flow. Nutrient capillary flow 
correlated inversely with SMAR throughout 
the experiment (P < 0.05). 
Portal venous pressure (PVP) rose sig- 
nificantly during glucagon infusion. Though 
assumed to be a reflection of the markedly 
increased SMAQ, the increase in PVP did 
not correlate with the rise in SMAQ or 
NCQ. Despite the relatively small volume 
of shunt flow, the increase in PVP during 
glucagon infusion correlated with the 
change in shunt flow at 30 min, at a time 
when AVAQ was not elevated above con- 
trol values. PVP did increase significantly 
with time throughout the experiment. 
DISCUSSION 
The presence and functional significance 
of arteriovenous anastomoses in the su- 
perior mesenteric artery circulation remain 
controversial [ 1, 5, 6, 9, 111. Investigators 
have reported variable results in deter- 
mining the percentage mesenteric shunt, 
from a negligible value to 41-51% shunt 
[ 11, 171. The former study used 44-pm 
spheres, and the latter used 8-pm spheres. 
Since the mean diameter of canine mesen- 
teric capillaries is approximately 7.38 
pm, results of experiments utilizing spheres 
small enough to traverse the capillary 
channels must be interpreted with caution 
[ 1, 171. Earlier studies using appropriately 
sized microspheres have indicated that 
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shunting in the canine superior mesenteric 
artery circulation accounts for approxi- 
mately 1 to 4% of this vessel’s normal 
blood flow [5, 6, 111. Although employing 
different techniques for estimation of shunt, 
these experiments yielded similar results. 
Delaney found 0.97% mean shunt in the 
mesenteric circulation using a needle in- 
jection into the superior mesenteric artery of 
anesthetized dogs, and a 2.89% baseline 
shunt using an indwelling mesenteric cathe- 
ter in the awake animal [5]. This investigator 
reported that spheres 20 pm in size were 
adequately trapped in the liver with only 
0.02% of their radioactivity lodged in the 
lungs following portal venous injection [5]. 
Similar results have been reported by other 
investigators [9]. Greenway and Oshiro 
reported that less than 0.3% of radioactivity 
injected into canine celiac artery and portal 
vein was found in the lung [lo]. 
Glucagon in pharmacologic doses has been 
reported to increase celiac, superior mesen- 
teric artery, pancreatic, and liver blood flow 
[2,4,7, 14, 15, 16, 19,21,25,27,28,29,30]. 
The increase in hepatic blood flow is thought 
due to an increase in both portal venous flow 
and hepatic artery flow [ 141. Glucagon sig- 
nificantly decreases vascular resistance in 
the hepatic, celiac, and superior mesenteric 
artery circulations, as well as significantly 
reducing total peripheral vascular resistance 
[19]. Glucagon has been shown to be a 
positive inotrope as well as positive chrono- 
trope [8, 221, and thus increases cardiac 
output. In the present experiment glucagon 
increased superior mesenteric artery blood 
flow out of proportion to the rise in cardiac 
output. This is consistent with previous 
reports in the literature, and indicates that 
glucagon acts as a selective mesenteric 
arterial dilator [ 191. 
Glucagon has been reported to increase 
portal venous pressure, increase portal 
venous oxygen concentration, and decrease 
splanchnic arteriovenous oxygen differ- 
ences [12, 131. Based on these findings, 
speculation arose that glucagon caused 
mesenteric arteriovenous anastomotic shunt- 
ing [12, 13, 20, 241. Other experiments 
using indirect methods examining oxygen 
consumption have not supported this con- 
tention [23]. To our knowledge, the effect of 
glucagon on mesenteric arteriovenous shunt- 
ing has not been previously measured 
directly. In the present study the fact that 
changes in portal venous pressure corre- 
lated significantly with the changes in su- 
perior mesenteric artery shunt flow only at 
30 min does not refute the assumption that 
glucagon increases mesenteric arteriove- 
nous anastomotic shunting. However, the in- 
creased volume of shunt flow induced by 
glucagon was miniscule compared to the 
increase in total nonshunted nutrient supe- 
rior mesenteric artery blood flow. Sig- 
nificant increases in portal venous pressure 
at 10 and 20 min during infusion did not 
correlate with shunt flow, which had already 
begun to decrease and was at its lowest 
mean value during glucagon infusion at 30 
min. It is difficult to believe that the in- 
crease in portal venous pressure was due 
solely to the small volume of increased 
shunt flow. 
This present study did not examine the 
distribution of blood flow within the gut 
wall. Glucagon has been shown to increase 
whole gut and villous tip blood flow in 
normal dogs [ 11. In addition, glucagon has 
been shown to increase blood flow to all 
layers of the gut during digoxin-induced 
vasoconstriction in the dog [27]. Increased 
superior mesenteric artery blood flow in the 
presence of both a significant SMA stenosis 
and concomitant digoxin-induced vasocon- 
striction has also been demonstrated ex- 
perimentally [ 181. In the present study 
glucagon did not increase the percentage 
shunt but transiently increased absolute 
shunt flow. These former results can be 
explained by drug-induced superior mesen- 
teric arteriolar dilatation with a passive 
increase in blood flow through AVAs and 
capillaries, both of which are presumably 
distal to the arterioles. These splanchnic 
hemodynamic effects of glucagon and the 
ability to achieve these effects by intra- 
venous, as opposed to selective intraarterial 
administration, make the drug a theoretically 
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attractive choice as an adjunct in the 15. 
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